A COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICACY of two formulations IN THE MANAGEMENT OF AMAVATA WITH SPECIAL REFERENCE TO RHEUMATOID ARTHRITIS

Phase 2

Conditions: Health Condition 1: M049- Autoinflammatory syndrome, unspecifiedHealth Condition 2: M049- Autoinflammatory syndrome, unspecifiedHealth Condition 3: M368- Systemic disorders of connective tissue in other diseases classified elsewhere

Registration Number: CTRI/2022/10/046235

Lead Sponsor: Dr Seeta MBiradar

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

PATIENTS diagnosed as having Amavata on the basis of signs and symptoms that are typically diagnosed as classical symptoms and Rheumatoid Arthritis on basis of ACR CRITERIA FOR DIAGNOSING RHEUMATOID ARTHRITIS

Exclusion Criteria

patients suffering from complications of Aamavata

Juveline RA Septic arthritis Rheumatic Heart Disease

RA with involvement of other organs.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Subjective parameters <br/ ><br>Sandhi shoola <br/ ><br>Sandhi shotha <br/ ><br>Sparshasahatva <br/ ><br>Stabdata <br/ ><br>Angamarda <br/ ><br>Aruchi <br/ ><br>Alasya <br/ ><br>Objective parameters <br/ ><br>C-RP <br/ ><br>ESR <br/ ><br>Anti-CCP <br/ ><br>RA factor <br/ ><br>Assesment will be done on Pain Swelling Morning stiffness Tenderness Fever ESR score C-RP score DAS 28 score Disability Index Quality of Life Index SF36 by adapting standard methods of scoring.Timepoint: OBJECTIVE PARAMETERS <br/ ><br>C-RP <br/ ><br>ESR <br/ ><br>RA factor <br/ ><br>Anti-CCP <br/ ><br>ASSESSMENT CRITERIA <br/ ><br>Assessment will be made for clinical signs and symptoms & investigations Statistical analysis <br/ ><br>package of version 20 will be done by using chi-square/Fisher’s test for subjective <br/ ><br>parameters & students t test for objective parameters. <br/ ><br>SAMPLE SIZE 120PATIENTS <br/ ><br>60 Patients in each group and treatment for 1month with follow up of 15days <br/ ><br>

Secondary Outcome Measures